US · OBIO
Orchestra BioMed Holdings, Inc.
Price · as of 2026-11-13
$7.25
Market cap 252.7M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Orchestra BioMed Holdings, Inc. (OBIO) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
- CEO
- David Hochman
- Employees
- 86
- Beta
- 0.48
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.